Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2 Power of likelihood ratio, log-rank, and Fisher’s exact tests as a function of the relative risk (RR) for different proportions of susceptible.

Published by署秀 路 Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 2 Power of likelihood ratio, log-rank, and Fisher’s exact tests as a function of the relative risk (RR) for different proportions of susceptible."— Presentation transcript:

1 Figure 2 Power of likelihood ratio, log-rank, and Fisher’s exact tests as a function of the relative risk (RR) for different proportions of susceptible animals. Solid lines denote the likelihood ratio test; long dashes, the log-rank test; and short dashes, Fisher’s exact test. Simulations assume equal allocation to the vaccine and control arms of the study, a total sample size of N=50, a c<sub>max</sub> (maximum no. of challenges per animal) of 10, and p<sub>0</sub>=0.5 as the per-challenge probability of infection for control animals. The horizontal gray line denotes the significance level α=0.05 From: Power to Detect the Effects of HIV Vaccination in Repeated Low-Dose Challenge Experiments J Infect Dis. 2009;200(4): doi: /600891 J Infect Dis | © 2009 by the Infectious Diseases Society of America 1

Download ppt "Figure 2 Power of likelihood ratio, log-rank, and Fisher’s exact tests as a function of the relative risk (RR) for different proportions of susceptible."

Similar presentations

Calculating sample size for a case-control study

Calculating sample size for a case-control study
American Academy of Pediatrics, Committee on Infectious Diseases. Policy Updated Recommendations on the Use of Meningococcal Vaccines Pediatrics. doi:

American Academy of Pediatrics, Committee on Infectious Diseases. Policy Updated Recommendations on the Use of Meningococcal Vaccines Pediatrics. doi:
Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.

Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.
Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.

Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.
Table 1. Baseline Characteristics of the 36,636 Study Subjects

Table 1. Baseline Characteristics of the 36,636 Study Subjects
Figure 1. Varicella-related outpatient visit rates by age group, MarketScan 2003–2012. Varicella was the primary diagnosis code for data shown. Annual.

Figure 1. Varicella-related outpatient visit rates by age group, MarketScan 2003–2012. Varicella was the primary diagnosis code for data shown. Annual.
Figure 1. Disposition of study participants, by group. Data are no

Figure 1. Disposition of study participants, by group. Data are no
Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.

Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.
Table 4 Results of 3 pairwise comparisons of expanded virus groups, by use of least-squares means differences and the Tukey honestly significant difference.

Table 4 Results of 3 pairwise comparisons of expanded virus groups, by use of least-squares means differences and the Tukey honestly significant difference.
Figure 1. Shiga toxin–producing Escherichia coli (STEC) isolates by method of initial detection and STEC serotype, Connecticut, 2000–2009. From: Ten-Year.

Figure 1. Shiga toxin–producing Escherichia coli (STEC) isolates by method of initial detection and STEC serotype, Connecticut, 2000–2009. From: Ten-Year.
Table 1 Groups of subjects in a study of the association between antibiotic use and colonization with resistant pneumococci. From: Measuring and Interpreting.

Table 1 Groups of subjects in a study of the association between antibiotic use and colonization with resistant pneumococci. From: Measuring and Interpreting.
Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria.

Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria.
Table 1 Characteristics of the 968 Women in the Study Group

Table 1 Characteristics of the 968 Women in the Study Group
Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.

Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.
Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking.

Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking.
Table 4 Comparison of frequencies of Legionella pneumophila serogroup 1 urinary antigen results and antibody titer results among patients with Pontiac.

Table 4 Comparison of frequencies of Legionella pneumophila serogroup 1 urinary antigen results and antibody titer results among patients with Pontiac.
From: Rotarix: A Rotavirus Vaccine for the World

From: Rotarix: A Rotavirus Vaccine for the World
Figure 3. Estimated liver parasite load on day 6

Figure 3. Estimated liver parasite load on day 6
Open Forum Infect Dis. 2014;1(suppl_1):S13-S14. doi: /ofid/ofu051.37

Open Forum Infect Dis. 2014;1(suppl_1):S13-S14. doi: /ofid/ofu051.37
Neonatal tetanus elimination in Pakistan: progress and challenges

Neonatal tetanus elimination in Pakistan: progress and challenges

Similar presentations

Ads by Google